A Phase I Clinical Trial of UX-GIP001 in the Treatment of Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy | MicrobiomeTrials← Back to trialsNCT07572812
A Phase I Clinical Trial of UX-GIP001 in the Treatment of Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2026-08-20Est. Completion: 2029-07-01
Enrollment target: 12 participants Locations- Beijing Tiantan Hospital, Capital Medical University, Beijing, Beijing Municipality, China
- The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
- West China School of Medicine and West China Hospital, Sichuan University, Chengdu, Sichuan, China
Other microbiome trials you might be interested in
ADHD - Attention Deficit Disorder With Hyperactivity
This is an observational study assessing the usage of stimulant medication for ADHD in the context of pediatric epilepsy…
Baltimore, United StatesEst. completion Dec 2030
Dravet Syndrome
ENDEAVOR is a Phase 1/2, 2-part, multicenter study to evaluate the safety and efficacy of ETX101 in participants with SC…
San Francisco, United StatesEst. completion Jan 2028
Recruiting
Brain Tumor Related Epilepsy (BTRE)
This is a supportive care study to assess the effect of Vitamin B6 supplementation on mood-related side effects of levet…
Durham, United StatesEst. completion May 31, 2027